

Form PTO-1449 (modified)		Atty. Docket No.: DEBE:069US	Serial No.: 10/589,450
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Malte Peters <i>et al.</i>	
		Filing Date: August 11, 2006	Group: 1641
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/BD/	C1	Franz <i>et al.</i> , "Exacerbation of Wegener's Granulomatosis following Single Administration of Monoclonal Antibody 17-1A (Panorex) during Adjuvant Immunotherapy of Colon Cancer," <i>Onkologie</i> , 23:472-474, 2000.
	C2	Frodin <i>et al.</i> , "Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules," <i>Cancer Res.</i> , 50:4866-4871, 1990.
	C3	Herlyn <i>et al.</i> , "Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody," <i>Cancer Res.</i> , 40:717-721, 1980.
	C4	Koprowski <i>et al.</i> , "Colorectal carcinoma antigens detected by hybridoma antibodies," <i>Somatic Cell Genet.</i> , 5:957-971, 1979.
	C5	Lewis, "Technology evaluation: ING-1, XOMA," <i>Curr. Opin. Mol. Ther.</i> , 5:433-436, 2003.
	C6	Litvinov <i>et al.</i> , "Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins," <i>J. Cell Biol.</i> , 139:1337-1348, 1997.
	C7	McLaughlin <i>et al.</i> , "An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy," <i>Cancer Immunol. Immunother.</i> , 48:303-311, 1999.
	C8	Mellstedt <i>et al.</i> , "Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma," <i>Ann. NY Acad. Sci.</i> , 910:254-261, 2000.
	C9	Riethmuller <i>et al.</i> , "Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial," <i>J. Clin. Oncol.</i> , 16:1788-1794, 1998.

25758390.1

EXAMINER: /Brad Duffy/

DATE CONSIDERED: 12/19/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DEBE:069US	Serial No.: 10/589,450
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Malte Peters <i>et al.</i>	
		Filing Date: August 11, 2006	Group: 1641
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/BD/	C10	Riethmuller <i>et al.</i> , "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group," <i>Lancet</i> , 343:1177-1183, 1994.
/BD/	C11	Spizzo <i>et al.</i> , "Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer," <i>Int. J. Cancer</i> , 98:883-888, 2002.

25758390.1

EXAMINER: /Brad Duffy/

DATE CONSIDERED: 12/19/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.